AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses.
Trending:
AstraZeneca to buy Alexion for $39 billion in rare-disease push